Identifying cdc7 as a synergistic target of chemotherapy in resistant small-cell lung cancer via crispr/cas9 screening

HIGHLIGHTS

  • who: Ling Deng from the Antibodies Antibodies used in this study are as follow: CDC7, MCM2, PARP, Caspase3, cleaved-Caspase3, Bcl-2, Bax, Cyclin, Cyclin, and GAPDH were purchased from Proteintech Group, UK have published the research: Identifying CDC7 as a synergistic target of chemotherapy in resistant small-cell lung cancer via CRISPR/Cas9 screening, in the Journal: (JOURNAL)
  • what: Based on the screening data and the fact that cell cycle inhibitors were hits for SCLC therapy, the authors focused on the role of CDC7 in chemo-resistant SCLC.
  • how: These data indicated . . .

     

    Logo ScioWire Beta black

    If you want to have access to all the content you need to log in!

    Thanks :)

    If you don't have an account, you can create one here.

     

Scroll to Top

Add A Knowledge Base Question !

+ = Verify Human or Spambot ?